SCHEMBL6038381

SCHEMBL6038381

O=S(=O)(Nc1nc2ccccc2nc1OCc1ccccn1)c1ccc(Br)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
LMNA P02545 2/20 0.56
HSD17B10 Q99714 2/20 0.56
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
ALDH1A1 P00352 6/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
RXFP1 Q9HBX9 3/20 0.55
HTT P42858 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
NPSR1 Q6W5P4 2/20 0.47
PKM P14618 2/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
POLB P06746 2/20 0.43
HRH4 Q9H3N8 1/20 0.42
TP53 P04637 1/20 0.41
HSP90AA1 P07900 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038903 0.91 KDM4E (0.67) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6154628 0.89 MEN1 (0.58) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6038930 0.89 MEN1 (0.70) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6039165 0.89 KDM4E (0.59) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6038810 0.88 KMT2A (0.57) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6038431 0.87 KDM4E (0.57) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6039424 0.87 KDM4E (0.60) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6038892 0.86 MEN1 (0.57) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6038585 0.86 KDM4E (0.53) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL6038514 0.85 KDM4E (0.57) KDM4ELMNAHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KDM4E 3561/4885LMNA 4821/4885HSD17B10 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.